View Older Stories View More Recent Stories
-
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
-
Halda Therapeutics Secures $126 Million Financing to Advance RIPTAC™ Cancer Therapies into the Clinic for Major Solid Tumors
-
Form SC 13D/A 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
IDRx Announces $120 Million Series B Financing to Advance Potential Best-in-class New Treatment for Gastrointestinal Stromal Tumor (GIST)
-
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
-
Dignify Therapeutics welcomes leading spinal injury expert Alexander "Sasha" Rabchevsky PhD, to its Scientific Advisory Board
-
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies into Clinical Development
-
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
-
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc.
-
Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias
-
Form SC 13D Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Magenta Medical Closes $105M Financing Led by Novo Holdings
-
Form SC 13G RECURSION PHARMACEUTICAL Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Praxis Precision Medicin Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
-
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
-
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
-
Form SC 13G Perceptive Capital Solut Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Aerovate Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Evolent Health, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-IL18 Immunoconjugate Program Into Clinical Trials
-
Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates
-
Form SC 13G BICYCLE THERAPEUTICS Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B
-
Form SC 13G Tourmaline Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G Structure Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Adela to Present Data Supporting Use of its Tissue-Agnostic MRD Assay for Recurrence Prediction and Monitoring in Patients with Head & Neck Cancer at the American Society of Clinical Oncology 2024
-
Gameto Raises $33 Million in Series B Financing to Advance Development and Commercialization of Novel Fertility Treatments
-
Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline
-
Be Biopharma Announces FDA Clearance of IND Application for BE-101 in Hemophilia B
-
Bicycle Therapeutics (BCYC) Announces $555 Million Private Placement Equity Financing
-
Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing
-
Be Biopharma Expands Scientific Advisory Board with the Appointment of Cell and Gene Therapy Leader Dr. Paula Cannon
-
AltruBio Secures up to $225M Oversubscribed Series B Financing to Advance the Clinical Development of Novel Immune Checkpoint Enhancer Program
-
Form 13F-HR/A RA CAPITAL MANAGEMENT, For: Mar 31
-
Form SC 13D/A Eliem Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Form SC 13D/A iTeos Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Ajax Therapeutics Raises $95 Million Series C Financing To Advance First-in-Class Type II JAK2 Inhibitor, AJ1-11095, Into The Clinic
-
Form SC 13G Medicenna Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia
-
iTeos Therapeutics (ITOS) Announces $120 Million Registered Direct Offering
-
iTeos Therapeutics Announces $120 Million Registered Direct Offering
-
Form SC 13D/A Black Diamond Therapeuti Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
